Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...

Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

The EU medicines regulator on Friday rejected Eli Lilly's (LLY.N), opens new tab Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not large enough to outweigh the ...

CHICAGO, March 30 (Reuters) - The highest dose of an experimental drug developed by Eli Lilly (LLY.N), opens new tab significantly reduced levels of a genetically inherited risk factor for heart ...

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...

European Medicines Agency advisers said Friday that Eli Lilly’s Alzheimer’s disease treatment should not be approved, once again diverging from their U.S. counterparts. The Committee for ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla (donanemab) also got a rejection from EU regulators.

(RTTNews) - Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living ...

CHICAGO (Reuters) -The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial ...

Experimental Lilly Drug Cuts Genetic Heart Disease Risk Factor by 94% in Trial By Julie Steenhuysen CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly ...